Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study

Abstract Introduction To assess the efficacy and safety of the subcutaneous (s.c.) secukinumab 150 mg with loading (150 mg) or without loading (150 mg no-load) regimen through 104 weeks in patients with active psoriatic arthritis (PsA) in the FUTURE 4 (NCT02294227) study. Methods Patients with PsA (...

Full description

Bibliographic Details
Main Authors: Alan J. Kivitz, Peter Nash, Hasan Tahir, Andrea Everding, Heřman Mann, Andrzej Kaszuba, Pascale Pellet, Albert Widmer, Luminita Pricop, Ken Abrams
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-06-01
Series:Rheumatology and Therapy
Subjects:
Biologics
Efficacy
Inflammation
Interleukins
Psoriatic arthritis
Safety
Online Access:http://link.springer.com/article/10.1007/s40744-019-0163-5

Internet

http://link.springer.com/article/10.1007/s40744-019-0163-5

Similar Items